Prof. Benjamin L. Miller completed his undergraduate studies at Miami University (Ohio), receiving degrees in Chemistry (BS), Mathematics (AB), and German (AB) in 1988. He next moved to Stanford University, where he carried out his PhD research in chemistry under the direction of Paul Wender. Following a stint as an NIH postdoctoral fellow at Harvard in Stuart Schreiber’s laboratory, he joined the University of Rochester faculty in 1996. His group’s expertise in molecular recognition, combinatorial chemistry, nanotechnology, and optical sensing has been applied to the development of novel optical biosensor platforms and synthetic compounds targeting several human diseases. He is currently Professor of Dermatology, Biochemistry and Biophysics, Biomedical Engineering, and Optics. As an entrepreneur, Miller is a founder of Adarza BioSystems, Inc., a multiplex optical biodetection company located in Rochester, NY and St. Louis, MO. He is also the Academic Lead for the Integrated Photonic Sensors working group in AIM Photonics.
Research in the Miller group focuses on two fundamental areas: the control of biomolecular interactions through the synthesis of new small-molecule probes, and the observation of biomolecular interactions through the development of novel optical sensing technologies. In the area of control, we are particularly interested in the sequence-selective recognition of RNA. New RNA sequences with important functions in basic biology and human health and disease are being discovered at an ever-increasing rate, and yet our ability to target these sequences specifically is still at a rudimentary stage. To address this gap, we are applying techniques of molecular design and a novel combinatorial method of small-molecule evolution called Dynamic Combinatorial Chemistry, which allows us to rapidly "prototype" sequence-selective RNA binding molecules. Thus far we have used this methodology to RNA targets important in Myotonic Dystrophy and HIV. Protein-targeted small-molecule discovery projects are also of interest, and current projects include the mechanism of tight junction formation and the transport of beta-amyloid across the blood-brain barrier. To the end of achieving better methods of observing biomolecular interactions, our group has a longstanding program in the use of the optical properties of nanostructured materials as the basis for new biosensors and diagnostic tools. Two examples of current efforts include Arrayed Imaging Reflectometry (AIR) and sensors based on two-dimensional photonic crystals (2-D PhC). AIR relies on the creation of a near-perfect antireflection coating on the surface of a silicon chip; binding of a biomolecular target destroys this antireflective condition and is visible by a change in reflected light. This allows for highly multiplexed (10's to 1000's of targets) and quantitative detection. Photonic crystal sensors, on the other hand, offer the possibility of ultrasensitive detection: for example, a major long-term goal of our work is the production of sensors that can effectively detect one virus in a blood sample.